Mucopolysaccharides (MPS) Typing - 24 Hrs Urine

Mucopolysaccharides (MPS) Typing - 24 Hrs Urine is a specialised biochemical investigation used to assess the quantity and pattern of glycosaminoglycans excreted during a complete 24-hour urine collection. Glycosaminoglycans, abbreviated as GAGs, were formerly called mucopolysaccharides. An abnormal urinary GAG pattern can support the investigation of mucopolysaccharidoses, a group of inherited lysosomal storage disorders.

Glycosaminoglycans are complex carbohydrate chains that form important components of cartilage, bone, skin, tendons, corneas, heart valves, blood vessels and connective tissues. The body continuously breaks down these molecules using specialised enzymes located inside lysosomes, which act as the recycling structures of cells.

When a specific lysosomal enzyme is deficient or does not function correctly, one or more GAGs cannot be degraded normally. Partially broken-down material accumulates within cells and tissues and may be excreted in increased quantities through urine. Progressive accumulation can affect the skeleton, joints, heart, airways, liver, spleen, eyes, ears and nervous system.

MPS typing provides more detailed information than a basic qualitative screening test. While a qualitative screen may only indicate whether an abnormal mucopolysaccharide finding is present, typing evaluates the GAG pattern to determine which fractions are increased. The detected pattern may help clinicians select the most appropriate enzyme assays and genetic tests for confirmation.

Depending on the laboratory method, the investigation may evaluate dermatan sulfate, heparan sulfate, keratan sulfate, chondroitin sulfate or related degradation products. Different combinations are associated with different MPS disorders. However, urine typing alone cannot provide a final diagnosis because patterns can overlap and some affected patients may have subtle or atypical findings.

Benefits of MPS Typing in 24-Hour Urine

A complete 24-hour collection measures GAG excretion across an entire day rather than relying on one random specimen. This may help reduce variations associated with urine concentration and time of collection. Accurate collection is essential because missed urine can falsely reduce the calculated excretion.

• Evaluates urinary glycosaminoglycan excretion over a complete 24-hour period.
• Provides more detailed pattern information than a basic qualitative urine screen.
• May help distinguish groups of MPS disorders based on the GAG fractions detected.
• Supports selection of appropriate lysosomal enzyme assays for confirmation.
• Contributes to the investigation of inherited metabolic and lysosomal storage diseases.
• May support monitoring in selected patients with a confirmed MPS disorder.
• Complements clinical examination, skeletal imaging and organ-specific assessments.
• Can guide molecular genetic testing when interpreted by a metabolic specialist.
• Provides an integrated daily measurement that is less dependent on one random urine concentration.
• Supports specialist counselling and further family evaluation after confirmation.

Understanding MPS Types and GAG Patterns

MPS I: MPS I results from deficiency of alpha-L-iduronidase and includes a spectrum historically described as Hurler, Hurler-Scheie and Scheie syndromes. Urine may show increased dermatan sulfate and heparan sulfate. Clinical severity varies considerably.

MPS II: MPS II, also called Hunter syndrome, is associated with deficient iduronate-2-sulfatase activity. Dermatan sulfate and heparan sulfate may be increased. Unlike most other MPS disorders, MPS II generally follows an X-linked inheritance pattern and predominantly affects males.

MPS III: MPS III, or Sanfilippo syndrome, consists of several subtypes caused by deficiencies in enzymes required to degrade heparan sulfate. Heparan sulfate elevation is characteristic. Neurological and behavioural manifestations may predominate over skeletal findings.

MPS IV: MPS IV, also called Morquio syndrome, includes types IVA and IVB. Keratan sulfate may be increased, while chondroitin-6-sulfate may also contribute to the pattern in MPS IVA. Skeletal abnormalities can be prominent, while intelligence is often preserved.

MPS VI: MPS VI, or Maroteaux-Lamy syndrome, is caused by arylsulfatase B deficiency. Dermatan sulfate is typically increased. Clinical features may resemble MPS I, but intellectual development may remain unaffected.

MPS VII: MPS VII, also called Sly syndrome, results from beta-glucuronidase deficiency. Dermatan sulfate, heparan sulfate and chondroitin sulfate patterns may be abnormal. Clinical presentation ranges from severe prenatal disease to attenuated later-onset forms.

The urinary pattern provides a biochemical direction but cannot always distinguish disorders with overlapping GAG profiles. Specific enzyme activity measurement and molecular genetic confirmation are therefore required.

Clinical Indications and Applications

Abnormal Initial MPS Screen: MPS typing may be requested after a qualitative urine test indicates increased mucopolysaccharides. Typing helps characterise the abnormality and guides subsequent enzyme testing.

Suggestive Clinical Features: Doctors may request the test directly when a patient has a combination of skeletal abnormalities, joint stiffness, coarse facial features, recurrent hernias, organ enlargement, airway problems, corneal clouding, hearing loss or developmental concerns.

Developmental and Neurological Changes: Certain MPS disorders may cause developmental delay, behavioural changes, sleep disturbance, learning difficulties, loss of acquired abilities or progressive neurological decline. The pattern and severity differ considerably between MPS types.

Skeletal and Joint Disorders: MPS can cause short stature, abnormal spinal curvature, chest-wall abnormalities, hip dysplasia, knock knees, joint stiffness, joint laxity and a characteristic radiological pattern called dysostosis multiplex.

Cardiac and Respiratory Findings: GAG accumulation can affect heart valves, heart muscle, coronary arteries, upper airways and lung function. Patients may experience recurrent respiratory infections, noisy breathing, snoring or obstructive sleep apnoea.

Monitoring Confirmed Disease: Quantitative or pattern-based GAG testing may be used in selected patients receiving enzyme replacement therapy, haematopoietic stem cell transplantation or other specialised management. The value of repeat testing depends on the MPS type, method and treatment protocol.

Why Doctors Recommend This Test

Mucopolysaccharidoses are progressive conditions, but early symptoms may be non-specific. A child may initially present with recurrent ear infections, hernias, delayed growth, joint problems or developmental differences. Recognising the overall pattern and performing appropriate biochemical testing can shorten the diagnostic journey.

Urine typing can identify whether dermatan sulfate, heparan sulfate, keratan sulfate or another relevant fraction is increased. This information helps the metabolic specialist determine which enzyme assay is most appropriate. For example, a pattern dominated by heparan sulfate may direct attention toward disorders such as MPS III, while increased keratan sulfate may support evaluation for MPS IV.

However, MPS typing should never be considered an independent final diagnosis. GAG patterns can overlap, vary with age and change with disease severity. Mild or attenuated disease can produce smaller abnormalities than severe early-onset disease. Modern mass-spectrometry methods may offer greater specificity than older electrophoretic techniques.

Preparation Before the Test

Fasting is generally not required unless the referring doctor provides specific instructions. The patient should maintain their usual diet and normal fluid intake. Excessive water consumption may increase urine volume substantially, while dehydration can produce a concentrated specimen.

Inform the doctor and laboratory about the patient's age, symptoms, family history, current medication, previous urine MPS results, enzyme tests, genetic studies and any disease-specific treatment. Age is essential because urinary GAG excretion changes during childhood and is naturally higher in younger children.

The laboratory will provide a suitable 24-hour urine container. It may contain a preservative depending on the analytical method. Do not remove, rinse or discard a preservative. Avoid direct skin contact and keep the container securely away from children.

How to Collect a 24-Hour Urine Sample

Step 1: Begin the collection at a convenient time, usually in the morning. Urinate into the toilet and discard this first specimen. Record the exact time as the collection start time.

Step 2: Collect every urine specimen produced after the recorded start time. This includes all urine passed during the day and night. Transfer each specimen into the laboratory container without losing any portion.

Step 3: Store the container according to the laboratory's instructions. Refrigeration or another cool-storage method may be required to preserve the specimen. Keep the lid tightly closed.

Step 4: At the same time the following day, urinate one final time and add this specimen to the container. This completes the 24-hour collection. Record the exact end time.

Step 5: Return the entire container promptly. Do not discard any urine or submit only a small portion unless the laboratory specifically instructs you to mix, measure and transfer an aliquot.

If any urine is missed, spilled or contaminated, contact the collection centre. The entire collection may need to be restarted because incomplete collection can falsely lower the measured GAG excretion.

Laboratory Analysis and Reporting

Traditional MPS typing may use electrophoresis or chromatography to separate urinary mucopolysaccharides into characteristic fractions. Modern laboratories may use liquid chromatography-tandem mass spectrometry to quantify specific GAG-derived disaccharides with greater analytical sensitivity and specificity.

The report may describe the pattern as normal, abnormal or suggestive of a particular group of MPS disorders. It may also provide numerical measurements for selected markers. Results must be interpreted using age-appropriate and method-specific reference intervals.

The report should not be used alone to assign an MPS subtype. The doctor may correlate the GAG pattern with enzyme activity, clinical phenotype and molecular genetic findings before confirming the diagnosis.

Normal Reporting Time

The report for the Mucopolysaccharides (MPS) Typing - 24 Hrs Urine test is generally available within 7 to 10 working days. Specialised separation, mass-spectrometry analysis, technical interpretation, repeat testing or referral-laboratory processing may affect turnaround time.

Who Should Consider This Test?

• Patients with a positive or abnormal qualitative urine MPS screen.
• Infants or children with unexplained developmental or neurological changes.
• Patients with short stature, abnormal bone development or progressive joint problems.
• Children with recurrent hernias, organ enlargement or frequent respiratory infections.
• Patients with corneal clouding, hearing loss, heart-valve disease or coarse facial features.
• Individuals with a family history of mucopolysaccharidosis.
• Patients with a confirmed MPS disorder requiring specialist-directed biochemical monitoring.
• Anyone advised to undergo testing by a paediatrician, clinical geneticist or metabolic specialist.

Understanding the Test Results

Normal Pattern: A normal result means that the laboratory did not identify a clear increase or abnormal distribution of the measured urinary glycosaminoglycans. This reduces the likelihood of several MPS disorders but does not exclude all types, attenuated disease or a low-excretion state.

Abnormal Dermatan Sulfate Pattern: Increased dermatan sulfate may occur in MPS I, MPS II, MPS VI and MPS VII. The pattern does not determine which enzyme is deficient, so targeted enzyme testing is necessary.

Abnormal Heparan Sulfate Pattern: Increased heparan sulfate may occur in MPS I, MPS II, MPS III and MPS VII. Clinical findings and specific enzyme analysis help narrow the differential diagnosis.

Abnormal Keratan Sulfate Pattern: Increased keratan sulfate may support investigation for MPS IV. Age and analytical method are important because keratan sulfate excretion can vary substantially.

Mixed or Non-Specific Pattern: More than one GAG fraction may be elevated, or the pattern may not clearly match a single disorder. Repeat analysis, quantitative testing and a broader lysosomal enzyme or genetic panel may be recommended.

After an abnormal result, confirmatory testing typically includes specific lysosomal enzyme measurement in leukocytes, plasma, cultured fibroblasts or dried blood spots. Molecular genetic testing can identify disease-causing variants, confirm the subtype and support carrier or family studies.

Clinical Limitations

Incomplete 24-hour collection is an important source of error. Missing one or more urine specimens can falsely reduce measured GAG excretion. Incorrect start or end times, contamination, improper storage and an inaccurate total volume can also affect the result.

Urinary GAG excretion is influenced by age, hydration, kidney function, disease type, severity and treatment status. Mild or attenuated MPS forms may show only subtle abnormalities, especially in older patients. Consequently, a normal result cannot completely exclude an MPS disorder when clinical suspicion is strong.

Patterns can overlap between MPS types, and typing cannot measure enzyme function directly. The test cannot determine carrier status, inheritance pattern or disease severity with certainty. A final diagnosis requires clinical correlation and usually enzyme and genetic confirmation.

Results produced by different analytical methods may not be directly comparable. Patients undergoing monitoring should preferably use the method and laboratory recommended by their metabolic treatment team.

Important Safety Information

This test supports specialist assessment and should not be used for self-diagnosis. A suspected or confirmed MPS disorder requires coordinated care that may involve metabolic medicine, genetics, cardiology, respiratory medicine, orthopaedics, neurology, ophthalmology, audiology, physiotherapy and other specialties.

Seek urgent medical care for breathing difficulty, severe sleep-related breathing problems, seizures, loss of consciousness, sudden weakness or rapid clinical deterioration. Patients with possible cervical spine instability should receive specialist evaluation before anaesthesia, surgery or procedures involving substantial neck movement.